American Scientists have created a new hope in the field of cardiovascular treatment that can save millions of life if its further testings become successful.
The Scientists of UNIGE, HUG and the University of Basel have developed a new device nanocontainer which they have named 'Time Bomb' for treating atherosclerosis – a state of cardiovascular disease in which fat deposits inside the walls of arteries and make them narrow.
Though there are various treatments available for it like nitroglycerin, which dilates the arteries, but it works on whole body, not only on diseased areas, resulting various side effects.
On the contrary, the newly found device nanocontainer works on only diseased areas, which reduces the side effects.
For developing 'Time Bomb' the team of the researchers developed nanocontainer by rearranging the structure of certain molecules in the form of lenticular lens that freely moves through the healthy arteries without breaking. This new 'Time Bomb' is perfectly stable, except when subjected to the shear stress of stenosed arteries – the state of narrow arteries.
"In brief, we exploited a previously unexplored aspect of an existing technology. This research offers new perspectives in the treatment of patients with cardiovascular disease," explained Andreas Zumbuehl from the Department of Organic Chemistry at UNIGE.
"The nano component is present in all disciplines, but the most interesting aspect of nanomedicine is its overview allowing the development of clinical products that integrate this global medical point of view from the earliest onset of research projects," added Bert Muller, Director of the Biomaterials Science Centre (BMC) at Basel.
Till Saxer of the Cardiology and General Internal Medicine Departments at HUG stated, "Nanomedicine is a discipline stemming from general nanoscience but which orients itself towards medical research. The interdisciplinary collaboration between chemistry, physics, basic science and clinical medicine in a highly technical environment could lead to a new era of research."
"The nano component is present in all disciplines, but the most interesting aspect of nanomedicine is its overview allowing the development of clinical products that integrate this global medical point of view from the earliest onset of research projects," added Bert Muller, Director of the Biomaterials Science Centre (BMC) at Base.
--With ANI Inputs--
|
|
Comments:
